EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 933 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia June 14, 2018 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 Load more HOT NEWS Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... Change Your Thoughts, Change Your World
